A phase III trial of the insulin-like growth factor 1 receptor inhibitor figitumumab showed no benefit in survival outcomes when added to standard chemotherapy in patients with advanced non–small-cell lung cancer.
Cisplatin, etoposide, and irinotecan outperformed topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC) in a Japanese trial, though there was substantially increased toxicity with the regimen.
The addition of ramucirumab to docetaxel improved outcomes over placebo with docetaxel as a second-line treatment of patients with advanced non-small-cell lung cancer (NSCLC), according to results of the REVEL trial.
Several factors affect physicians’ choice of genomic tests, including availability, speed, and cost. Traditionally allelotyping have been used, since they are fast and sensitive, even though they are not comprehensive.